Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of March 31, 2016:
- Total Issued Shares: 5,362,243,151 Ordinary Shares of 25p each.
- Treasury Shares: 491,505,950 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,870,737,201.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,870,737,201) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) to calculate the net outstanding share count.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K does not contain financial results.